A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

Trial Profile

A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Nivolumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 548
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 May 2018 Planned End Date changed from 8 Jan 2022 to 1 Aug 2023.
    • 07 May 2018 Planned primary completion date changed from 29 May 2019 to 11 Feb 2022.
    • 03 Oct 2017 Planned primary completion date changed from 17 Jul 2019 to 29 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top